Laropiprant recalled


Merck & Co has said it is recalling Tredaptive cholesterol tablets in response to trial results that raised safety concerns and the recommendations of a European Medicines Agency safety panel.

Tredaptive tablets are approved in the EU and elsewhere – but not in the US – for treating patients with high cholesterol levels. They contain niacin (vitamin B3), which increases levels of ‘good’ HDL cholesterol, and laropiprant, a patent protected compound designed to reduce facial flushing, a common side effect of taking niacin.

The data suggest that the tablets are not as effective as hoped at reducing heart attacks, deaths and strokes in patients with high levels of ‘bad’, LDL cholesterol. They also suggest that the side effects are worse than expected.

Merck & Co said that doctors should stop prescribing the drug and review treatment plans for patients already taking it.

US regulators rejected laropiprant for market approval in 2008.


Related Content

HDL drug class struggling after latest flop

27 May 2012 Business

news image

The failure of another 'good' cholesterol-raising drug and a new genetic study casts shadow over HDL hypothesis

Regulator rebuffs Merck's cholesterol drug

28 May 2008 News Archive

news image

The US Food and Drug Administration (FDA) has unexpectedly refused to approve Merck's cholesterol-lowering drug Cordaptive

Most Read

Flushing advice is flawed

24 August 2015 Research

news image

Protocols to restore contaminated water supplies are not based on science

Simple chemistry saving thousands of gold miners from mercury poisoning

25 August 2015 News and Analysis

news image

Basic apparatus is cutting mercury pollution and helping Indonesian miners go for gold

Most Commented

New drug treatment for alcoholism shows promise in animal studies

24 August 2015 Research

news image

Compounds that target a receptor in the brain appear less addictive with fewer negative side-effects than existing drugs

A risky business

28 August 2015 In the Pipeline

news image

Graduate research is likely the most risky time of a chemist’s career, says Derek Lowe